Hesperos and GATC Health Partner to Build FDA-Aligned NAMs Workflow

|

Integrating GATC Health’s Operon® AI modeling with Hesperos’ multi-organ Human-on-a-Chip® systems will establish a repeatable, human-relevant testing workflow to accelerate IND-enabling studies and reduce reliance on animal models.

ORLANDO, FLORIDA, 18 November 2026: Hesperos, Inc., a global leader focused on improving preclinical drug development with its Human-on-a-Chip® (HoaC) single- and multi-organ system platforms, has entered into a strategic collaboration with tech-bio company GATC Health Corp to build an integrated New Approach Methodologies (NAMs) workflow designed to cut the time and costs of preclinical testing ahead of human clinical trials.

The collaboration pairs GATC Health’s proprietary Operon® AI predictive modeling platform with Hesperos’ serum-free, human cell-based HoaC platform. As detailed in the official joint press release, the companies will initially apply this combined in silico and in vitro workflow to GATC-1021, GATC Health’s non-opioid drug candidate in development for opioid use disorder (OUD), to generate human-relevant nonclinical data supporting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

Collaboration Highlights & Outcomes

The effort will combine Operon’s in silico modeling of off-target binding profiles, and central nervous system (CNS) pathways associated with addiction with Hesperos’ HoaC platform containing functional human neural, cardiac, and hepatic circuits to provide confirmatory, clinically relevant functional readouts of efficacy, on and off-target toxicity, along with pharmacokinetic/pharmacodynamic (PK/PD) parameters.

Why It Matters

As noted by Jayson Uffens, Co-Founder and CTO of GATC Health, “This collaboration is about building a repeatable way to combine AI prediction with human cell-based data.” James Hickman, PhD, Co-Founder and CSO of Hesperos further emphasized, “Partnering with GATC Health to pair our Human-on-a-Chip microphysiological models with their Operon AI predictions creates a continuous loop of human-focused data. Using GATC-1021 as a real-world case study will show how NAMs can help inform and de-risk development ahead of an IND filing.”

Discover how we can advance your pipeline faster and more efficiently

Explore Other Hesperos News

GATC Banner 4

Hesperos and GATC Health Partner to Build FDA-Aligned NAMs Workflow

Integrating GATC Health’s Operon® AI modeling with Hesperos’ multi-organ Human-on-a-Chip® systems will establish a repeatable, human-relevant testing workflow to accelerate IND-enabling studies and reduce reliance on animal models. ORLANDO, FLORIDA, 18 November 2026: Hesperos, Inc., a … Read More

Malaria Grant Announcement

Hesperos Awarded NIH Phase II Grant to Advance Malaria-on-a-Chip Platform for Novel Therapeutics

Funding from the National Institute of Allergy and Infectious Diseases (NIAID) will expand Hesperos’ physiologically relevant Malaria-on-a-Chip model to bridge critical translational gaps and accelerate the evaluation of next-generation antimalarial therapies. ORLANDO, FLORIDA, 22 October 2026: … Read More

Page Resize for White Bar Removal - 1

Hesperos and UCF Showcase First-of-its-Kind Human-on-a-Chip® Comorbidity Model to Accelerate Drug Discovery for Aging Populations

Hesperos and UCF publish new study in Alzheimer’s and Dementia demonstrating peripheral neuromuscular pathology is NOT CNS dependent in Alzheimer’s Disease